103 related articles for article (PubMed ID: 15792677)
1. Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor.
Bartok A; Steiner S; Seidinger D; Jetzl A; Huber K; Minar E; Stefenelli T; Kopp CW
Thromb Res; 2005; 115(6):469-74. PubMed ID: 15792677
[TBL] [Abstract][Full Text] [Related]
2. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
Sanguigni V; Pignatelli P; Lenti L; Ferro D; Bellia A; Carnevale R; Tesauro M; Sorge R; Lauro R; Violi F
Circulation; 2005 Feb; 111(4):412-9. PubMed ID: 15687128
[TBL] [Abstract][Full Text] [Related]
3. HMG-CoA reductase inhibitors may affect thrombin generation by reducing factor VII activity in hyperlipidemic patients.
Ural AU; Avcu F
Thromb Res; 2006; 118(5):665-6. PubMed ID: 16360198
[No Abstract] [Full Text] [Related]
4. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.
Mobarrez F; He S; Bröijersen A; Wiklund B; Antovic A; Antovic J; Egberg N; Jörneskog G; Wallén H
Thromb Haemost; 2011 Aug; 106(2):344-52. PubMed ID: 21614411
[TBL] [Abstract][Full Text] [Related]
5. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
Chyrchel M; Rakowski T; Rzeszutko L; Legutko J; Dziewierz A; Dubiel JS; Dudek D
Kardiol Pol; 2006 Dec; 64(12):1357-62; discussion 1363. PubMed ID: 17206539
[TBL] [Abstract][Full Text] [Related]
6. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
[TBL] [Abstract][Full Text] [Related]
7. Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels.
Agledahl I; Brodin E; Svartberg J; Hansen JB
Thromb Haemost; 2009 Nov; 102(5):945-50. PubMed ID: 19888533
[TBL] [Abstract][Full Text] [Related]
8. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
[TBL] [Abstract][Full Text] [Related]
9. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.
Patti G; Chello M; Pasceri V; Colonna D; Nusca A; Miglionico M; D'Ambrosio A; Covino E; Di Sciascio G
J Am Coll Cardiol; 2006 Oct; 48(8):1560-6. PubMed ID: 17045888
[TBL] [Abstract][Full Text] [Related]
10. Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial.
Leone AM; Rutella S; Giannico MB; Perfetti M; Zaccone V; Brugaletta S; Garramone B; Niccoli G; Porto I; Liuzzo G; Biasucci LM; Bellesi S; Galiuto L; Leone G; Rebuzzi AG; Crea F
Int J Cardiol; 2008 Nov; 130(3):457-62. PubMed ID: 18667247
[TBL] [Abstract][Full Text] [Related]
11. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
Patti G; Pasceri V; Colonna G; Miglionico M; Fischetti D; Sardella G; Montinaro A; Di Sciascio G
J Am Coll Cardiol; 2007 Mar; 49(12):1272-8. PubMed ID: 17394957
[TBL] [Abstract][Full Text] [Related]
13. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
Mitsios JV; Papathanasiou AI; Elisaf M; Goudevenos JA; Tselepis AD
Platelets; 2005 Aug; 16(5):287-92. PubMed ID: 16011979
[TBL] [Abstract][Full Text] [Related]
14. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels.
Agledahl I; Brodin E; Svartberg J; Hansen JB
Thromb Haemost; 2009 Mar; 101(3):471-7. PubMed ID: 19277407
[TBL] [Abstract][Full Text] [Related]
15. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
Kuryata OV; Yegorova YV
Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
[TBL] [Abstract][Full Text] [Related]
16. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation.
Stefanadi E; Tousoulis D; Antoniades C; Katsi V; Bosinakou E; Vavuranakis E; Triantafyllou G; Marinou K; Tsioufis C; Papageorgiou N; Latsios G; Stefanadis C
Int J Cardiol; 2009 Apr; 133(2):266-8. PubMed ID: 18187214
[TBL] [Abstract][Full Text] [Related]
17. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
18. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes.
Golino P; Ravera A; Ragni M; Cirillo P; Piro O; Chiariello M
Circulation; 2003 Dec; 108(23):2864-9. PubMed ID: 14656922
[TBL] [Abstract][Full Text] [Related]
19. The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation.
Lean SY; Ellery P; Ivey L; Thom J; Oostryck R; Leahy M; Baker R; Adams M
Haematologica; 2006 Oct; 91(10):1360-6. PubMed ID: 17018385
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
